Treatment Trials

2 Clinical Trials for Various Conditions

Focus your search

      COMPLETED
      A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
      Description

      This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb23104 monotherapy and combination therapy with ipilimumab in subjects with selected advanced solid tumors.

      Conditions
      Melanoma (Excluding Uveal Melanoma)Cervical CarcinomaPancreatic CarcinomaBreast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 NegativeHepatocellular CarcinomaUrothelial CarcinomaSquamous Cell Carcinoma of the Head and NeckNasopharyngeal CarcinomaRenal Cell CarcinomaColorectal CarcinomaEndometrial CarcinomaNon-small Cell Lung CarcinomaSmall Cell Lung CancerGastric or Gastroesophageal Junction AdenocarcinomaAdvanced Solid TumorsUndifferentiated Pleomorphic Sarcoma
      Talk to us
      ACTIVE_NOT_RECRUITING
      Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors
      Description

      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of intravenous (IV) administration of XmAb808 in combination with pembrolizumab in subjects with selected advanced solid tumors and to identify the minimum safe and biologically effective/recommended dose (RD) and schedule for XmAb808.

      Conditions
      Head and Neck Squamous Cell CarcinomaMelanoma Excluding Uveal MelanomaNon-small Cell Lung Cancer, Squamous or Non-squamousUrothelial CarcinomaRenal Cell Carcinoma, Clear CellCastration-resistant Prostate CancerOvarian Cancer, EpithelialTNBC - Triple-Negative Breast CancerColorectal Cancer
      Talk to us